Dr. Peter Brier and Nurse Practitioner Kelly McCormack discuss two new medications recently approved by the Food & Drug Administration.
Opill is the first over-the-counter birth control pill that will become available in the US in 2024. Made by Perrigo, Opill is a progestin-only oral contraceptive; the concerns of the FDA, and potential side effects are examined.
Leqembi (Lecanemab) is a new drug produced by the Japanese pharmaceutical firm Eisei. The monoclonal antibody medication is designed for early-stage Alzheimer's patients; the discussion focuses on Leqembi's potential, but also the question of what occurs as the disease progresses over time.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive
https://www.reuters.com/markets/europe/new-alzheimers-drug-holds-promise-adds-cost-pressures-medicare-2023-07-13/
Dr. Peter Brier and Nurse Practitioner Kelly McCormack discuss two new medications recently approved by the Food & Drug Administration.
Opill is the first over-the-counter birth control pill that will become available in the US in 2024. Made by Perrigo, Opill is a progestin-only oral contraceptive; the concerns of the FDA, and potential side effects are examined.
Leqembi (Lecanemab) is a new drug produced by the Japanese pharmaceutical firm Eisei. The monoclonal antibody medication is designed for early-stage Alzheimer's patients; the discussion focuses on Leqembi's potential, but also the question of what occurs as the disease progresses over time.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive
https://www.reuters.com/markets/europe/new-alzheimers-drug-holds-promise-adds-cost-pressures-medicare-2023-07-13/